Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the ten analysts that are covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $16.22.

FOLD has been the subject of several recent analyst reports. UBS Group increased their price target on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Wall Street Zen cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company cut their target price on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, February 20th. Finally, The Goldman Sachs Group decreased their target price on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd.

Amicus Therapeutics Trading Down 0.6%

Shares of NASDAQ:FOLD traded down $0.04 during midday trading on Tuesday, hitting $6.22. The company had a trading volume of 2,822,292 shares, compared to its average volume of 2,840,115. Amicus Therapeutics has a 12 month low of $5.81 and a 12 month high of $12.65. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The stock has a market cap of $1.92 billion, a price-to-earnings ratio of -34.56, a PEG ratio of 1.51 and a beta of 0.64. The firm has a fifty day simple moving average of $7.11 and a 200 day simple moving average of $8.71.

Hedge Funds Weigh In On Amicus Therapeutics

Several large investors have recently modified their holdings of FOLD. HealthInvest Partners AB boosted its holdings in shares of Amicus Therapeutics by 18.6% during the fourth quarter. HealthInvest Partners AB now owns 326,840 shares of the biopharmaceutical company's stock worth $3,076,000 after acquiring an additional 51,368 shares during the period. Tempus Wealth Planning LLC bought a new stake in shares of Amicus Therapeutics during the fourth quarter worth approximately $259,000. Intech Investment Management LLC boosted its holdings in shares of Amicus Therapeutics by 59.7% during the fourth quarter. Intech Investment Management LLC now owns 124,704 shares of the biopharmaceutical company's stock worth $1,175,000 after acquiring an additional 46,633 shares during the period. Norges Bank bought a new position in Amicus Therapeutics during the 4th quarter worth $29,033,000. Finally, Renaissance Technologies LLC increased its position in Amicus Therapeutics by 174.1% during the 4th quarter. Renaissance Technologies LLC now owns 2,108,616 shares of the biopharmaceutical company's stock worth $19,863,000 after buying an additional 1,339,316 shares during the period.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.